T2807
Thymidine Phosphorylase, recombinant from Escherichia coli
recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL
Synonym(s):
Thymidine:orthophosphate deoxy-D-ribosyltransferase
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
CAS Number:
UNSPSC Code:
12352204
NACRES:
NA.54
MDL number:
Recombinant:
expressed in E. coli
Concentration:
≥500 units/mL
recombinant
expressed in E. coli
form
buffered aqueous solution
concentration
≥500 units/mL
UniProt accession no.
storage temp.
2-8°C
Quality Level
Gene Information
Escherichia coli K12 ... deoA(948901)
Looking for similar products? Visit Product Comparison Guide
General description
Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation.
Application
Thymidine phosphorylase has been used in a study to assess TAS-102 treatment in patients with advanced solid tumors. Thymidine phosphorylase has also been used in a study to investigate antitumor effects of the FP3 protein on patient-derived tumor tissue xenograft models of primary colon carcinoma.
Biochem/physiol Actions
An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway.
An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway. This pathway allows pyrimidine bases to be recycled for nucleotide biosynthesis, while the pentose 1-phosphates are converted to intermediates of the pentose phosphate shunt and glycolysis. The E. coli thymidine phosphorylase shares 40% sequence homology with the human sequence, which has been found to be identical to the angiogenic agent platelet-derived endothelial growth factor. The purified E. coli enzyme has been shown to stimulate blood vessel growth in chick chorioallantoic membrane assays.
Physical form
Solution in 0.5 M potassium phosphate containing 2 mM uracil, 0.02% sodium azide and bovine serum albumin
Preparation Note
Cloned from E. coli and produced in overexpressing E. coli
Other Notes
One unit will convert 1.0 μmole each of thymidine and phosphate to thymine and 2-deoxyribose 1-phosphate per min at pH 7.4 at 25°C.
Storage Class
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Regulatory Information
常规特殊物品
含少量动物源组分生物产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Domenico Ribatti et al.
Expert opinion on therapeutic targets, 16(12), 1215-1225 (2012-09-18)
Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help
Jian Zhang et al.
Cancer chemotherapy and pharmacology, 71(1), 103-113 (2012-10-12)
The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer
Charlotte Gasson et al.
Journal of pharmaceutical and biomedical analysis, 72, 16-24 (2012-11-14)
Erythrocyte encapsulated thymidine phosphorylase (EE-TP) is under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a fatal metabolic disorder resulting from an inherited deficiency of the enzyme thymidine phosphorylase. We report here the development and validation of
T Doi et al.
British journal of cancer, 107(3), 429-434 (2012-06-28)
TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. TAS-102 was administered twice daily on days 1-5 and days 8-12 in
Ketao Jin et al.
Cancer biology & therapy, 13(9), 737-744 (2012-05-24)
FP3 is an engineered protein which contains the extracellular domain 2 of VEGF receptor 1 (Flt-1) and extracellular domain 3 and 4 of VEGF receptor 2 (Flk-1, KDR) fused to the Fc portion of human immunoglobulin G 1. Previous studies
Related Content
QC Methods
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service